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Abstract
Background: Ventral intermediate thalamic nucleus (VIM) deep brain stimulation (DBS) is an effective treatment for
tremor, but there is limited data on long-term efficacy and mortality after VIM-DBS. Here we report the analysis of
patient satisfaction and mortality in all patients treated in our center 1996–2010 with VIM-DBS for essential tremor (ET).
Methods: Forty-six consecutive patients were included in this study. Medical records were reviewed, and a follow-up
questionnaire was sent to all surviving patients.
Results: Seventy percent of all possible participants (26 patients) answered the questionnaire. Follow-up time for the
responding patients was median 6.0 years (2–16). Median self-reported score on visual analogue scale of the initial
postoperative effect on tremor was 8.5 (0.1–10), with a significant reduction to 7.4 (0–10) at follow-up (p = 0.001).
Patients reported a median score of 10 (0–10) for overall patient satisfaction with VIM-DBS treatment. Eight patients
(17%) died after median 8.9 years (0.6–15) after surgery, at median age 77.4 years (70–89). One patient (2%) committed
suicide seven months after the operation. Calculated standard mortality ratio among ET patients was 1.3 (CI 0.6–2.6),
similar to the general population.
Conclusion: We found no significant increase in mortality in this cohort of VIM-DBS operated ET patients compared to
the general population in Norway. The patients reported high long-term satisfaction and continuing effect of VIM-DBS
on tremor even after many years. VIM-DBS therefore seems to be an effective symptomatic long-term treatment of ET.
However, one patient committed suicide. Only one other suicide has previously been reported after VIM-DBS. It is
therefore still unclear whether VIM-DBS increases suicide risk.
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Background
Tremor is a common sign in movement disorders and
can in advanced cases lead to severe loss of daily func-
tion. Deep brain stimulation (DBS) of the ventral inter-
mediate nucleus (VIM) of the thalamus was introduced
by Benabid et al. [1,2] for tremor in Parkinson’s disease
(PD) in 1987 and for essential tremor (ET) in 1991.
Today DBS is commonly used in PD, but the subtha-
lamic nucleus is usually the preferred target since VIM-
DBS is not efficient for other parkinsonian symptoms
[3]. VIM-DBS can also be valuable in dystonic tremor
[4], but the internal segment of pallidum is usually the
preferred target in dystonic patients [5].
Several studies have confirmed that VIM-DBS is ef-
fective in ET [6-9], and the method is well established as
a symptomatic treatment for severe medically resistant
tremor. There are however, several reports of a gradually
diminishing effect on tremor over time [10,11]. To our
knowledge there are no previous studies of mortality
after DBS for ET. Some authors describe an increased
rate of suicide following DBS. Most of these articles ad-
dress the incidence of suicide after STN-DBS [12]. We
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have only found one previous description of a suicide
after VIM-DBS [13].
We have performed a retrospective study of all pa-
tients with ET receiving VIM-DBS in our hospital from
1996 to 2010. Herein we report analysis of patient satis-
faction and self-reported effect of VIM-DBS, adverse ef-
fects and mortality.
Methods
Study population and data acquisition
All 46 patients who underwent VIM-DBS surgery for ET
at Oslo University Hospital from 1996 to 2010 were in-
cluded in this retrospective study. The indication for
VIM-DBS was severe and incapacitating tremor with un-
satisfactory response to medical treatment. ET was diag-
nosed according to the consensus statement of the
Movement Disorder Society on tremor [14]. All patients
were followed until November 1, 2012, or death.
Data were obtained from patient records, from a new
20-item questionnaire (in Norwegian; Additional files 1
and 2) sent to all surviving patients, and from the Nor-
wegian Death Registry. Death statistics were obtained
from Statistics Norway (SSB), and mortality data for one
year (2006) representative for the period were used. In
the 20-item questionnaire, overall patient satisfaction
and self-reported treatment effect were measured by
visual analog scales (VAS). The patients were asked to
report treatment effect both during the initial postopera-
tive period after a stable effect of VIM-DBS had been
obtained, and after long-term treatment (in 2012). The
questionnaire also contained questions about work per-
formance and psychiatric co-morbidity. Written informed
consent was obtained from all participants. The Regional
Committee for Medical and Health Research Ethics in
South-East Norway approved the study (REK 2011/2459),
and permissions to use data from deceased patients were
obtained from The Norwegian Directorate of Health and
The Norwegian Data Protection Authority.
Surgical procedure
Preoperative MRI sequences from the day before the op-
eration were merged with a stereotactic CT scan per-
formed after the stereotactic frame had been mounted.
Targets and electrode trajectory were planned using the
iPlan®(version 3.0) computer-aided neuronavigation sys-
tem (BrainLAB, München, Germany). The VIM target
was planned using our standard stereotactic coordinates
in relation to the anterior commissure (AC)-posterior
commissure (PC) line: approximately 30% of the AC-PC
distance anterior to PC, 50% of the AC-PC distance lat-
eral of the midline and 0-2 mm superior to the AC-PC
line. The target was adjusted in some patients with ab-
normal ventricles and according to the symptoms, so
that the target was 12 mm (narrow ventricles and main
symptoms in lower extremity) - 16 mm (wide ventricles
and main symptoms in upper extremity) lateral to the
midline. After clinical test stimulation in the awake patient,
confirming good tremor suppression and no unacceptable
side effects, a permanent quadripolar electrode (model
3387 or 3389, Medtronic, MN, USA) was inserted.
Electrode position was checked using perioperative
radiography. With six exceptions all patients were op-
erated bilaterally. Both electrodes were implanted dur-
ing the same operation. Finally, the electrodes were
connected to a subcutaneous infraclavicular pulsegen-
erator (Kinetra, Soletra and Activa PC from Medtronic) via
a subcutaneous extension cable. This was done under
general anesthesia. Of the 40 patients receiving bilat-
eral stimulation, two had previously received unilateral
stimulation. Four patients had earlier been treated with
unilateral thalamotomy.
Statistical analysis
Many of the measured parameters were not normally
distributed, and non-parametric tests were used in the
analysis. P-value < 0.05 was considered statistically sig-
nificant. Mortality in ET patients was compared to the
general population of Norway using standard mortality
ratio (SMR). SPSS software version 16.0. was used for
statistical analysis.
Results
Outcome
There were 14 (30%) women and 32 (70%) men included in
the study. Median follow-up time was 5.5 years (0.6-16)
and median age at final evaluation was 71.6 years (39–90).
Among all 46 patients, eight had died and one was un-
able to participate due to cognitive impairment. Thus,
37 patients received the questionnaire, and twenty-six of
these (70%) responded. Median follow-up time of the
responding patients was 6.0 years (2–16).
Stimulation parameters registered in the patient jour-
nal 3–8 years after surgery were available in 30 patients
(Table 1B). A significant increase was seen from the first
postoperative year to follow-up, both in median voltage,
2.3 V to 3.5 V (p = 0.001), and frequency, 148 Hz to 181 Hz
(p = 0.001). The median pulse width was unchanged.
Effect of VIM-DBS on tremor was reported retrospect-
ively in the questionnaire by 26 patients (Table 2B). Me-
dian self-reported VAS-score on initial postoperative
effect was 8.5 (0.1-10) in all responders. This was signifi-
cantly reduced to 7.4 (0.1-10) at follow-up (p = 0.001).
The median score for overall satisfaction with VIM-DBS
treatment was 10 (0–10).
VIM-DBS showed no statistically significant effect
on the working situation in our patients. Eight of 26
responding patients reported to be on disability benefit
before VIM-DBS surgery. Only one patient reported to
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regain full working ability after VIM-DBS treatment,
while one patient reported to be able to work part
time.
Adverse effects and battery replacements
Serious adverse effects were rare. One patient (2%) de-
veloped a superficial infection nine days after implant-
ation and was treated with antibiotics. Table 2C shows
self-reported adverse effects after VIM-DBS. There was
no significant increase in self-reported psychiatric symp-
toms after VIM-DBS implantation. However, one patient
reported a temporary increase of depressive symptoms
after surgery that had declined until follow-up. Another
patient with a previous history of depression got an ex-
acerbation of depressive symptoms, that did not decline
until follow-up.
On November 1, 2012 the original battery was still
functioning in 14 patients after median 2.7 years (2–6.3).
The battery had been replaced in 29 patients after me-
dian 3.7 years (2.0-8.5). In connection with battery re-
placement, three (10%) patients got an infection and
were treated with antibiotics. One of these developed
meningitis and the electrodes were removed, but were
later replaced.
Mortality
Eight patients (17%) died during the follow-up period (2
women, 6 men). The median time from surgery to death
was 8.9 years (0.6-15), and the median age at death was
77.4 years (70–89). Median age at surgery among the pa-
tients who died during follow-up was 71.8 (60–84), com-
pared to a median age at surgery of 65.2 for those who
survived. One patient (2%) committed suicide during an
episode of acute depression about seven months after
surgery. This 73 year old ET patient had to our know-
ledge no prior history of psychiatric disease, and DBS
tremor suppression was excellent at the last examination
six months after VIM-DBS surgery.
The mortality in ET patients was calculated using
standard mortality ratio (SMR). Calculated expected
deaths were 6.35, while eight deaths were observed. This
gave a standard mortality ratio of 1.26 with a 95% confi-
dence interval of 0.54 - 2.48 (p > 0.05). 10 years survival
rate after VIM-DBS operation was above 80% (Figure 1).
Discussion
Our study shows that the total survival 10 years after
VIM-DBS implantation in ET patients (Figure 1) is
above 80%. Louis et al. [15] have indicated that the mor-
tality in ET patients not treated with DBS is increased
relative to a control group without ET. We found no sig-
nificant increase in mortality in VIM-DBS treated ET
patients compared to the general Norwegian population
(calculated SMR 1.26).
There are several limitations to this comparison of
mortality in ET patients. The total number of patients
included in this study is relatively small. Because of this,
Table 1 Data from patient records
A: Epidemiological characteristics of patients treated with VIM-DBS
All (N = 46)
Sex M/F 32/14
Age at operation 65.2 (29.5-84.2)
Earlier unilateral DBS 2
Earlier thalamotomi 4
B: Stimulation parameters during long-term VIM-DBS treatment
Unilateral/bilateral 4/26
Voltage postoperative 2.3 (1.5–4)
Voltage follow-up 3.5 (2.1–4.4)
Puls width postoperative 90 (60–120)
Puls width follow-up 90 (60–120)
Frequency postoperative 148 (90–230)
Frequency follow-up 181 (120–230)
Data from patient records presented as median (range). Follow-up until
01.11.12 or death 1A. M: male, F: female. 1B. All: essential tremor patients.
Table 2 Data from patient self-report questionnaires
A: Medication for tremor
Number of patients N = 26 Yes No Unknown
Preoperative 12 (46) 11 (42) 3 (12)
Postoperative 5 (19) 16 (62) 5 (19)
At follow-up 9 (35) 12 (46) 5 (19)
B: Patient self-report
All (N = 26)
VIM-DBS effect on tremor postoperative 8.5 (0.1-10)
VIM-DBS effect on tremor at follow-up 7.4 (0.1-10)
Overall satisfaction with VIM-DBS 10 (0–10)
C: Most common adverse effects with VIM-DBS
Variable All
Number of patients 26
Dysarthria 17 (65)
Headache 9 (35)
Parestesia 6 (23)
Abnormal taste 8 (31)
Dizziness 5 (19)
Discomfort tongue 4 (15)
Reduced balance or coordination 4 (15)
Other 8 (31)
Patient self-report from follow-up questionnaire. Median follow-up 6.0 years
(range, 2–16).
2A. Data are given in number of patients = n (%) reporting use of medication
for tremor including betablockers, antiepileptics, benzodiazepines.
2B. VAS scale 1–10, where 0 is no effect of VIM-DBS on tremor and 10 is
maximum effect.
2C. Data given in number of patients = n (%) experiencing adverse effects.
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a possible modest increase in mortality would not give a
significant increase in SMR and could therefore escape
recognition. However, the group of patients included is
relatively large compared to most other studies of ET
patients. Another factor that might affect our results
could be that ET patients selected for surgery have less
comorbidity than those excluded.
One of our VIM-DBS patients committed suicide
within seven months after surgery. Increased suicide rate
after DBS has been indicated by several authors, but we
have found only one previous description of a suicide
after VIM-DBS [16]. Burkhard et al. [13] described a
4.3% suicide rate after DBS, and found no relationship to
the underlying condition or DBS target. Most reports
have discussed suicide risk after subthalamic nucleus
DBS in PD patients [12], but a recent randomized, con-
trolled multicentre study found no direct association be-
tween DBS surgery and an increased risk for suicide
ideation and behaviors in PD patients [16]. Therefore, it
is still unclear whether, or to which extent, there is an
increased suicide risk after DBS, and whether the risk
varies between different DBS targets.
The results from the patient questionnaire are ham-
pered by its retrospective design, with both recall- and
selection bias. Another problem is the wide range of
follow-up times due to the low number of patients oper-
ated each year. Patient satisfaction is difficult to assess,
and there are no validated methods to measure this in
our patient group. We used VAS-scores, since these
have shown to have good validity and reliability for pa-
tient satisfaction after other interventions [17]. Seventy
percent of the eligible participants responded to the
questionnaire. The median VAS-score for the postopera-
tive effect of VIM-DBS on tremor reported was high
(Table 2B). At follow-up, a modest, but significant effect
reduction was reported compared to the postoperative
score. In spite of this, a median VAS-score of 7.4 for the
effect of VIM-DBS on tremor after median 6.0 years
follow-up, indicate that VIM-DBS has a good long-term
effect on ET in most patients (Table 2A). Median VAS-
score of overall patient satisfaction with VIM-DBS treat-
ment in the questionnaire responders was high.
VAS-scale was also used by Zhang et al. [18] in their
long term study. At 56.9 months follow-up they found a
1.43 (±2.62) mean score for the effect of VIM-DBS on
tremor in ET patients. Some other studies have also re-
ported a decrease in activities of daily living (ADL) and
an increase in tremor at long-term follow-up, indicating
a loss of benefit of VIM-DBS over time or disease pro-
gression [10,11]. Compared to these reports, our results
seem to indicate a better long-term effect of DBS on
tremor, similar to what was described in a few other
long-term studies of ET [6,7,9].
Stimulation parameters were increased both for volt-
age and frequency from the first postoperative year until
follow-up. These findings are similar to previous reports
on ET [6,7,9]. Whether this increase in stimulation pa-
rameters and the loss of effect of VIM-DBS on tremor in
ET patients is related to disease progression or tolerance
to the VIM-DBS treatment, is still unclear.
Dysarthria was the most frequent reported adverse
effect. Similar findings have been reported from other
Follow up years
46 29 16 1 0 Patients at risk
Figure 1 Kaplan Meier curve constructed using death as outcome.
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DBS studies, especially after bilateral stimulation [9,19].
One of two responding patients with unilateral VIM-
DBS also reported dysarthria in the follow up question-
naire. Disequilibrium and balance difficulty together
with reported falls have also been used as a caution
against bilateral stimulation [9]. However, coordination
problems and dizziness were not reported as severe
problems in our study (Table 2C).
As in other studies of patients with ET [9,10] there is
a larger proportion of men compared to women treated
with DBS (2/3), despite that the prevalence of ET seems
to be equal in men and women [20]. Whether this has a
cultural or a gender dependent explanation is difficult to
tell, but similar is observed also in PD patients treated
with DBS [21-23].
Conclusions
We found no significant increase in mortality in ET pa-
tients treated withVIM-DBS when compared to the general
population of Norway. The estimated overall survival rate
after VIM-DBS is high, but one patient committed suicide
seven months after surgery. The adverse effects are gener-
ally well tolerated, and the patients report high long-term
satisfaction with the treatment, with a continuing effect of
VIM-DBS on tremor. Bilateral VIM-DBS therefore seems
to be an effective symptomatic long-term treatment of ET,
with a favorable risk-benefit profile.
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